Please login to the form below

Not currently logged in
Email:
Password:

drug reimbursement

This page shows the latest drug reimbursement news and features for those working in and with pharma, biotech and healthcare.

China updates drug reimbursement list, agrees price cuts

China updates drug reimbursement list, agrees price cuts

Drugs added include AbbVie's Humira and Roche's Perjeta. Chinese regulators have added 70 new medicines to the country’s National Reimbursement Drug List (NRDL), and has agreed an average ... The key drugs which have been added to the list include

Latest news

  • Chi-Med cues up two more regulatory filings in cancer Chi-Med cues up two more regulatory filings in cancer

    in the China National Reimbursement Drug List (NRDL) at the next update later this year. ... Within two years, To expects Chi-Med to become “a fully integrated and globally-facing biopharmaceutical company with capability to discover, develop and

  • Orphan drugs market to soar to $224bn by 2024 Orphan drugs market to soar to $224bn by 2024

    orphan drug product in 2024, and will help bring in total orphan drug sales of $13.7bn for the company. ... in 2018 versus $33, 654 for a non-orphan drug, explain much of the allure,” says the report.

  • Urovant slips on phase 3 incontinence drug data Urovant slips on phase 3 incontinence drug data

    As tolterodine is generically available that has raised questions about whether doctors would be prepared to prescribe vibegron – and moreover if insurers would back reimbursement of the drug – ahead of a ... If approved, it would become the first

  • Drug pricing is pharma’s top concern in 2019 Drug pricing is pharma’s top concern in 2019

    Drug pricing and reimbursement remains at the forefront of pharma executive minds as 2019 gets underway, according to a new industry survey. ... Unphased by the data, Trump told a cabinet meeting this week that “you’re going to see a tremendous

  • Better together when buying medicines? Taking stock of the BeNeLuxA initiative Better together when buying medicines? Taking stock of the BeNeLuxA initiative

    Apply that to the fragmented and diverse landscape of drug pricing and reimbursement in Europe and the reality becomes a lot more complicated. ... There is MEDEV too, an informal cooperation on the assessment, pricing and reimbursement of medicines in

More from news
Approximately 37 fully matching, plus 56 partially matching documents found.

Latest Intelligence

  • BRIC markets BRIC markets

    Drug reimbursement lists. All the BRIC nations have lists of medicines reimbursed at government level. ... Michael Kleinrock said: “China has had a national reimbursement drug list since 2001, which was updated in 2004 and then again in 2009, but then

  • Novel endpoints in the digital age Novel endpoints in the digital age

    Every clinical trial has an endpoint, a measure used to determine if the drug in question provides therapeutic benefit. ... This direct-from-patient data through novel endpoints allows researchers to address patients’ concerns about their disease

  • Is China ready for a pharmaceutical gold rush?

    The country’s single-payer system hasn’t been tested at this price level, making reimbursement uncertain. ... However, recently announced provincial reimbursement drug lists (PRDLs) will provide possible new opportunities for US pharmaceutical

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    The central government has also updated its national reimbursement drug list (NRDL) to include more and more innovative treatments, although this list remains restricted and is not regularly updated. ... While it didn’t make the cut onto the revised

  • ‘Flexible working’: fashionable buzzword or fundamental business operation? ‘Flexible working’: fashionable buzzword or fundamental business operation?

    Externally, there are the usual issues: downward pressure on hourly rates, reduced client budgets, environmental pressures on new drug development and licensing/reimbursement.

More from intelligence
Approximately 7 fully matching, plus 21 partially matching documents found.

Latest appointments

  • Extension for head of Germany’s VFA Extension for head of Germany’s VFA

    She has led the industry voice during an unsettled time for pharma in Germany with many companies critical of the AMNOG system of drug reimbursement introduced in 2010, which has seen

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics